Comanche Biopharma
Making every pregnancy around the world safer
- Headquarters
- Concord, Massachusetts
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- comanchebiopharma.com
- Total Funding
- $155.0M
- Last Round
- $40.0M Extension RoundJan 2026
About
Comanche Biopharma is a clinical-stage biopharmaceutical company developing CBP-4888, an investigational siRNA medicine for preterm preeclampsia. Founded in 2020 and headquartered in Concord, MA, Comanche's mission is to develop and make globally available the first therapy targeting a root cause of preeclampsia — a life-threatening pregnancy complication affecting millions of women worldwide. The EMA granted Orphan Drug Designation for CBP-4888 in 2025.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account